Registration gives the benefit of receiving regular site update emails.
ADHD Institute Register

Pharmacological interventions are recommended by clinical guidelines for ADHD as part of a comprehensive treatment programme (including a behavioural therapy component) if there is insufficient response to non-pharmacological treatment.1-5

The main classes of available ADHD pharmacological treatments include:

Stimulants

  • Methylphenidate (e.g. Ritalin®,6 Medikinet®,7 Biphentin®,8 Concerta®,9 Equasym®,10 Focalin®,11 Matoride®12)
  • Amfetamine (e.g. Adderall®,13 Amfexa®,14 Dexedrine®,15,16 Elvanse®,17 Elvanse Adult®18).

Non-stimulants

  • Atomoxetine (Strattera®19)
  • Guanfacine (Intuniv®20).

The decision about which medication should be used to treat ADHD depends on a range of factors, including: presence of comorbidities; undesirable effects of the medication; individual compliance needs; potential for drug diversion; and the personal preference of patients and their caregivers.1-5,21

 

Are there difficult areas of the day when control of ADHD symptoms is particularly important for children and adolescents with ADHD, for example, early morning, late afternoon, weekends, at school? | Dr Robert Findling | John Hopkins University and Kennedy Krueger Institute, Maryland, USA


When choosing the most appropriate treatment for your patient with ADHD, what consideration do you give regarding the flexibility of dosing? | Professor Peter Hill | Independent Child and Adolescent Psychiatrist, London, UK


When choosing a treatment, how big a consideration are the ADHD patients’ co-morbid conditions or co-morbid symptoms?  How do you decide which symptoms to treat? | Professor Peter Hill | Independent Child and Adolescent Psychiatrist, London, UK


When choosing a treatment, how big a consideration are the ADHD patients’ co-morbid conditions or co-morbid symptoms?  How do you decide which symptoms to treat? | Dr Robert Findling | John Hopkins University and Kennedy Krueger Institute, Maryland, USA


How does treating adults with ADHD differ from treating children and adolescents? | Dr Joel Young | Rochester Centre for Behavioral Medicine, Michigan, USA


Are there difficult areas of the day when control of ADHD symptoms is particularly important for children and adolescents with ADHD? | Professor Peter Hill | Independent Child and Adolescent Psychiatrist, London, UK


Mode of action

The modes of action of pharmacological treatments for ADHD are not fully understood; however, agents such as methylphenidate, amfetamine, atomoxetine and guanfacine all appear to have distinct effects on dopamine and noradrenaline signalling pathways in the brain.22-34

Mechanisms of delivery

Pharmacological treatments for ADHD can be delivered by immediate-release35 or extended-release (multiple bead,10,36-38 osmotic-controlled release,39,40 prodrug17,18,41,42) systems.

Pharmacokinetics

Pharmacokinetic data are available for all simulant and non-stimulant preparations.6-11,13-20,37,38,43-50

Differential response to treatment

Evidence from crossover studies suggests that some people with ADHD may respond differently to different types of pharmacological treatment, and that particular treatments may be ineffective in some patients.51-54

Adherence to treatment

Adherence to ADHD medication is often suboptimal, which can negatively affect treatment outcomes.55,56

Psychoeducation and knowledge of a patient’s acceptance of their condition may be helpful in encouraging adherence to medication, particularly in adolescents.5

Effect size

In the absence of direct comparative trials, effect sizes are calculated to allow indirect comparisons of randomised, double-blind, placebo-controlled studies of ADHD medications, and provide data on the relative efficacy of each medication.57-59

  1. Taylor E, Döpfner M, Sergeant J, et al. European clinical guidelines for hyperkinetic disorder — first upgrade. Eur Child Adolesc Psychiatry 2004; 13(Suppl 1): I/7-I/30.
  2. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. Available at: https://www.nice.org.uk/guidance/cg72/resources/attention-deficit-hyperactivity-disorder-diagnosis-and-management-975625063621. Last updated 2016. Accessed 05 January 2017.
  3. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014; 28: 179-203.
  4. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010; 10: 67.
  5. Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines. Toronto: CADDRA, 2011.
  6. Ritalin Summary of Product Characteristics. Novartis Pharmaceuticals UK Ltd. Last updated 05 May 2015.
  7. Medikinet Summary of Product Characteristics. Flynn Pharma Ltd. Last updated 10 September 2015.
  8. Biphentin Product Monograph. Purdue Pharma. Last updated 10 June 2016.
  9. Concerta XL 18-36mg Summary of Product Characteristics. Janssen-Cilag Ltd. Last updated 14 January 2015.
  10. Equasym XL Summary of Product Characteristics. Shire Pharmaceuticals Ltd. Last updated 10 March 2014.
  11. Focalin XR US Prescribing Information. Novartis Pharmaceuticals Corporation. Last updated June 2015.
  12. Matoride XL Summary of Product Characteristics. Sandoz Ltd. Last updated 02 December 2015.
  13. Adderall XR Canadian Product Monograph. Last updated 23 September 2015.
  14. Amfexa Summary of Product Characteristics. Flynn Pharma Ltd. Last updated 06 June 2016.
  15. Dexedrine Product Monograph. Paladin Labs Inc. Last updated 21 March 2016.
  16. Dexamfetamine Sulphate Summary of Product Characteristics. Auden Mckenzie (Pharma Division) Ltd. Last updated 01 August 2016.
  17. Elvanse Summary of Product Characteristics. Shire Pharmaceuticals Ltd. Last updated 13 September 2016.
  18. Elvanse Adult Summary of Product Characteristics. Shire Pharmaceuticals Ltd. Last updated 13 June 2016.
  19. Strattera Summary of Product Characteristics. Eli Lilly and Company Ltd. Last updated 08 June 2015.
  20. Intuniv Summary of Product Characteristics. Last updated 10 December 2015.
  21. Remschmidt H. Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 2005; 14: 127-137.
  22. Easton N, Steward C, Marshall F, et al. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 2007; 52: 405-414.
  23. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit / hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699-711.
  24. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155: 1325-1331.
  25. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006; 60: 1111-1120.
  26. Wall SC, Gu H, Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 1995; 47: 544-550.
  27. Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007; 129: 397-410.
  28. Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010; 68: 854-860.
  29. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006; 6: 6.
  30. Crunelle CL, van den Brink W, Dom G, et al. Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD. Br J Psychiatry 2014; 204: 486-487.
  31. Zhu MY, Shamburger S, Li J, et al. Regulation of the human norepinephrine transporter by cocaine and amphetamine. J Pharmacol Exp Ther 2000; 295: 951-959.
  32. Avelar AJ, Juliano SA, Garris PA. Amphetamine augments vesicular dopamine release in the dorsal and ventral striatum through different mechanisms. J Neurochem 2013; 125: 373-385.
  33. Liang NY, Rutledge CO. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol 1982; 31: 983-992.
  34. Pifl C, Agneter E, Drobny H, et al. Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology 1999; 38: 157-165.
  35. Gupta A, Hunt RL, Shah RB, et al. Disintegration of highly soluble immediate release tablets: a surrogate for dissolution. AAPS PharmSciTech 2009; 10: 495-499.
  36. Maldonado R. Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate. Expert Opin Drug Metab Toxicol 2013; 9: 1001-1014.
  37. Medikinet XL Summary of Product Characteristics. Flynn Pharma Ltd. Last updated 17 June 2014.
  38. Ritalin LA Summary of Product Characteristics. Novartis Pharmaceuticals Corporation. Last updated 29 June 2015.
  39. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006; 22: 1879-1892.
  40. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J Clin Pharmacol 2000; 40: 379-388.
  41. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010; 6: 317-327.
  42. Sharman J, Pennick M. Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells. Neuropsychiatr Dis Treat 2014; 10: 2275-2280.
  43. Adjei A, Teuscher NS, Kupper RJ, et al. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin((R))) in healthy adult volunteers. J Child Adolesc Psychopharmacol 2014; 24: 570-578.
  44. Gonzalez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 2002; 40: 175-184.
  45. Haessler F, Tracik F, Dietrich H, et al. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers. Int J Clin Pharmacol Ther 2008; 46: 466-476.
  46. Tuerck D, Wang Y, Maboudian M, et al. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J Clin Pharmacol Ther 2007; 45: 662-668.
  47. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008; 48: 293-302.
  48. Haffey MB, Buckwalter M, Zhang P, et al. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. Postgrad Med 2009; 121: 11-19.
  49. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 53-63.
  50. Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007; 29: 617-625.
  51. Arnold LE. Methylphenidate vs amphetamine: comparative review. J Atten Disord 2000; 3: 200-211.
  52. Hodgkins P, Shaw M, Coghill D, et al. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 2012; 21: 477-492.
  53. Efron D, Jarman F, Barker M. Methylphenidate versus dextroamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997; 100: E6.
  54. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165: 721-730.
  55. Marcus SC, Wan GJ, Kemner JE, et al. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005; 159: 572-578.
  56. Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011; 27(Suppl 2): 13-22.
  57. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 2009; 34: 678-694.
  58. Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T 2008; 33: 700-711.
  59. Cohen J. Statistical power analysis for the behavioral sciences. New York, NY: Academic Press, Inc, 1977.
Filter content by:
Filter content by:

ADHD Institue logo

You’re now being transferred to

and are leaving the ADHD Institute site

Shire has no influence or control over the content of this third party website.

Continue Cancel